Comparative Control vs. Reference Control: Why Your Implant Study Control Selection Matters

Every implantation study under ISO 10993-6:2026 is built on a comparison. Your test sample goes in alongside a control, and the tissue responses to both are evaluated side by side. The conclusion — whether your device produces an acceptable local tissue response — depends entirely on what that comparison shows.

That makes control selection one of the most consequential decisions in implant study design. Get it wrong and borderline histopathology results become very difficult to interpret, and difficult-to-interpret results are the kind that generate FDA questions you don't want.

ISO 10993-6:2026 added a dedicated section on control selection — Section 4.3 — and introduced formal definitions for both control types that weren't in the previous edition. Here's what the standard requires and what it means practically.

Two Types of Controls, Different Purposes

A comparative control is a medical device or material with a history of safe clinical use, used as a point of comparison for a new device seeking regulatory approval. The idea is that your test article is being evaluated against something that is already known to be acceptable in clinical use.

A reference control is a material with known properties that is considered generally inert in terms of biological local tissue effects and has been established on a historical basis within a pharmacopeia or similar standard. The most commonly used reference control is high-density polyethylene (HDPE), which serves as a procedural baseline.

These are not interchangeable. They answer different questions, and the standard's preference is clear.

The Standard's Preference: Comparative Control First

For non-absorbable medical devices or materials, ISO 10993-6:2026 requires that a comparative control be used — one made of a stable non-absorbable material with established clinical history. The standard is direct: ideally, a commercially available material should be used as a comparative control so the tissue reaction is similar to what has been clinically proven.

The logic is straightforward. If you're developing a new spinal implant, the most meaningful comparison is against a spinal implant material that is already on the market and known to be safe. That comparison tells you whether your device behaves like something that works in patients. A comparison against HDPE tells you whether your device is more or less reactive than a laboratory reference material — useful as a baseline, but much weaker as a safety argument.

When a comparative control is used, the standard also recommends including reference materials from ISO 10993-12:2021, Annex A as additional procedural controls, yielding a total of three articles in the study: the test sample, the comparative control, and the reference control. The reference control in this configuration serves as a check on study execution, not as the primary comparator.

When a Reference Control Is Appropriate

A reference control becomes the primary comparator when no appropriate comparative control exists. This is explicitly recognized in ISO 10993-6:2026: if no commercially available comparative material or medical device exists, the choice of a control that is as close as possible is preferred.

This applies most often to novel materials — new polymers, new composites, new surface technologies — where there is no established clinical comparator. In those cases, HDPE or another pharmacopeial reference material provides a known-inert baseline. But the standard is clear that this is a fallback, not a preference, and the limitations of the comparison need to be acknowledged in the study report.

There's a specific caution in ISO 10993-6:2026 worth understanding: HDPE as a reference control is appropriate for solid, smooth, non-absorbable materials. If your test article is a porous mesh, a gel, a powder, or an absorbable device, the physical characteristics of HDPE are so different that the tissue response comparison may be difficult to interpret. A porous implant can score higher than solid HDPE due to tissue ingrowth — not because the material is reactive, but because the physical form changes how tissue responds. That's a contextual interpretation issue that must be addressed in the study report, and one that sometimes comes back as an FDA question.

Geometry and Physical Form Matter as Much as Material

Control selection isn't only about material composition. ISO 10993-6:2026 is specific that the geometric and physical characteristics of the control — shape, size, curvature, and especially surface condition including porosity and texture — should be as similar to the test article as is practical. Any deviations must be explained, justified, and recorded.

This is where studies can run into trouble. A manufacturer might select a clinically established material as their comparative control but use a disc-shaped control against a rod-shaped test article, or a smooth-surfaced control against a textured implant. The mismatch in physical form changes the tissue environment around each sample, making the comparison less clean.

The standard's guidance that comparative control samples should be matched as closely as reasonably possible for physical properties and geometrical characteristics applies to the entire control article, not just its chemical composition.

Absorbable Materials: An Additional Layer of Complexity

For absorbable and degradable materials, control selection is more complicated because the tissue response changes as degradation proceeds. The standard requires that similar absorbable comparative controls be considered — materials with absorption rates similar to the test article.

Where no clinically relevant absorbable comparative control exists, a non-absorbable comparative control can be used with justification. But ISO 10993-6:2026 notes that since absorbable materials encounter changing tissue responses as degradation proceeds at rates that differ based on composition, processing, and sterilization, the tissue reaction to an absorbable test article may differ significantly from a non-absorbable comparator simply because of the degradation process — not because of a safety concern. That distinction has to be addressed in the study evaluation.

For absorbable materials, the regional draining lymph nodes must also be collected and microscopically evaluated, as degradation products can migrate to lymphoid tissue. ISO 10993-6:2026 expanded its guidance on lymph node assessment, and the new Annex G on microscopic evaluation of tissue responses covers this in detail. For non-absorbable materials, lymph nodes should be collected and fixed for possible future microscopic evaluation, with macroscopic alterations triggering microscopic examination.

What Happens When Control Selection Goes Wrong

The most common practical consequence of poor control selection is ambiguity in histopathology interpretation that lands in your FDA submission as a question or deficiency.

If you chose HDPE as your primary control for a porous absorbable scaffold, your scoring results may show elevated inflammatory cell scores compared to HDPE — not because your device is problematic, but because tissue ingrowth into porous structures and the degradation response naturally produce a different histopathological picture than inert, solid HDPE. If that context isn't clearly established in the study report and the biocompatibility evaluation, an FDA reviewer unfamiliar with the specific tissue dynamics may interpret the elevated scores as a safety concern.

ISO 10993-6:2026 directly addresses this: the nature of any adverse inflammatory response or high reactivity rating shall be discussed in the context of the control article chosen. That discussion needs to be in the study report and carried through into the biocompatibility evaluation report submitted to FDA.

The choice of control shall be documented and justified. If no control or a sham control is used, that must also be documented and justified.

What This Means for Study Planning

Control selection is a decision that needs to happen before the study starts, not during data interpretation. Once you have histopathology results, you're working with what the study gave you. If the control wasn't the right choice, your options for fixing that after the fact are limited.

The questions to answer upfront: Is there a commercially available implant with established clinical acceptability whose composition and physical form match your test article? If yes, that's your comparative control and the standard requires it for non-absorbable materials. If no, what reference control material best matches your test article's physical form? What limitations does that comparison introduce, and how will those limitations be addressed in the report?

Implantation Study Design and Medical Device Consulting

Control selection, study design, and histopathology interpretation for implant studies require specialized knowledge of ISO 10993-6:2026 requirements and how that data will be reviewed by FDA.

At JL Tox Consulting, we help medical device manufacturers and CROs design implantation studies that generate defensible data and support clear biocompatibility conclusions.

Our implantation testing and medical device consulting services include:

• Implantation study design including control selection strategy and justification documentation

• Biological evaluation planning under ISO 10993-1:2025 to determine when implantation testing is required

• Study protocol review before studies begin

• Histopathology interpretation support and biocompatibility evaluation report preparation

• FDA submission support integrating implantation data into 510(k), PMA, and De Novo biocompatibility packages

• Deficiency response preparation addressing FDA questions on implantation study design and interpretation

With over a decade of specialized experience in medical device biocompatibility and FDA regulatory submissions, Dr. James Lyons and the JL Tox team provide the expertise needed to get implantation studies right from the start.

Contact JL Tox Consulting to discuss your implantation study design:

Email: info@JLTox.com

Phone: (877) 899-6568